EMQN CIC & Informed Genomics: validating lab results
24 September 2024, Birmingham & Manchester, UK – Informed Genomics, the UK-based genomic testing laboratory delivering innovative ISO accredited services, has been selected by EMQN CIC to provide tumour profiling services to support their quality assurance services. Informed Genomics offers comprehensive next-generation sequencing (NGS) cancer mutation analyses from solid tumour and cell-free DNA in a […]
The new 2025 catalogue is now available!
We are proud to present to you the new EQA schemes for 2025, allowing more flexibility, time and cost efficiency, ease of purchase, and more. Our goal is to ensure the highest genomic diagnostic quality from lab to patient, and our updated schemes will help you get there, tailoring our services to your needs. Some of […]
In 2025, flexibility is our goal
You spoke and we listened! In 2025, we will be piloting changes to our scheme portfolio to enable more flexibility when participating in EQA. New for 2025, the hereditary hearing loss scheme has options to participate in EQA for either targeted DFNB1 locus testing, or for gene panel testing, enabling you to choose the […]
The new 2025 catalogue is coming soon… with some big changes
You spoke and we listened! We are updating our catalogue and some of our EQA schemes based on your feedback to better meet the needs of laboratories. We have reduced the maximum number of molecular pathology cases from ten to five, to save analysis costs and time. We are increasing the number of schemes for […]
EMQN to introduce innovative EQA Scheme for MT-RNR1 POCT
As the healthcare landscape has begun to rely increasingly on the use of point-of-care testing at, or close to, the patient’s bedside, it is crucial to ensure those tests are accurate and reliable, since immediate clinical decisions are based on the outcomes where even the slightest error could have profound consequences. EMQN CIC has introduced […]
EMQN & SensID launch ctDNA extraction EQA scheme
EMQN CIC and SensID GmbH are pleased to announce a strategic partnership to deliver a new External Quality Assessment (EQA) / Proficiency Testing (PT) scheme for circulating tumour DNA (ctDNA) extraction from plasma. Background The use of molecular testing to aid in determining therapy options for the treatment of non-small cell lung cancer (NSCLC) is now […]